News and Announcements
Announcing the Launch of Empower Group O Care
The Red Cross is thrilled to introduce Empower Group O Care, an innovative initiative set to tackle one of the most pressing issues in transfusion medicine today – ensuring a sustainable and reliable supply of O negative Red Blood Cells. As an industry leader with extensive expertise in transfusion medicine, we are championing responsible stewardship practices of both O negative and O positive blood through ongoing educational events and supportive hospital resources, including toolkits and reference documents.
Empower Group O Care underscores our collective obligation to act now to ensure life-saving blood products are consistently available to those who need them most. Join us as we work together to better steward this vital blood supply and support improved patient outcomes.
Events
Adverse Reaction to Transfusion: Laboratory Investigation (Part 1)
Date: April 21
Adverse Reaction to Transfusion: Laboratory Investigation (Part 2)
Date: April 22
Foundations of IgA Deficiency
Date: April 23
Laboratory Services Case Studies: IRL Case - Specialized Testing Case
- HLA Case
Date: April 24
Media Messaging Toolkit
The American Red Cross welcomes participation of our hospital partners in the recruitment of blood donors, especially in times of critical shortages. For your convenience, we have made available prepared messaging and graphics that can be used to promote the need for blood donations.
PLUS Online
An Educational Resource for Transfusion Medicine
What Are CAR-T Cells and What Is the American Red Cross Doing About Them?
T-cells play a pivotal role in the immune system’s response to cancer. Unlike B-cells which make antibodies, T-cells act directly in a cell-to-cell fashion. CAR-T stands for chimeric antigen receptor T-cells. The word “chimeric” means having parts from two or more origins. To accomplish this, T-cells are collected from the blood of a patient or […]
Continue ReadingCold-Stored Platelets and Room Temperature Platelets
With the introduction of cold-stored platelets (CSP) into practice, transfusion services have encountered challenges in interpreting FDA guidance. The FDA indicates that CSP may be used to treat active bleeding when conventional platelets—room temperature platelets (RTP)—are unavailable or impractical to use.1 In addition, the FDA requires transfusion services to develop standard operating procedures (SOPs) that […]
Continue Reading